Fabrazyme Market Could Grow With Dialysis Patients, Women, Children
Executive Summary
Genzyme expects the Fabry disease incidence in dialysis patients to nearly double the market for its Fabry therapy Fabrazyme
You may also be interested in...
Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed
FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval
TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model
Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions
CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes
The Centers for Medicare & Medicaid Services' self-injectables guidelines would still divide Medicare coverage within a therapeutic drug class based on route of administration